中图分类号 R956；R979.1 文献标志码 A 文章编号 1001-0408(2025)11-1370-05

    DOI 10.6039/j.issn.1001-0408.2025.11.14

    ABSTRACT OBJECTIVE From the perspective of China’s healthcare system，to evaluate the cost-effectiveness of tislelizumab in patients with locally advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC) whose disease progresses or is intolerable after receiving platinum-containing dual chemotherapy in the past. METHODS Rationale-303 research data were used to construct a partitioned survival model. The model period was set to be 21 days and simulated to 120 months. Using quality-adjusted life year(QALY)as a health output index，the incremental cost-effectiveness ratio(ICER)was calculated by discounting cost and health output with a discount rate of 5% . Single-factor sensitivity analysis and probability sensitivity analysis were performed to verify the robustness of the basic analysis results. RESULTS Cost-utility analysis results showed that the ICER of tislelizumab group was 65 653.52 yuan/QALY ......